Pomerantz LLP has filed a class action lawsuit against Fractyl Health and certain officers for allegedly making false and misleading statements about the efficacy of their diabetes and obesity treatment, Revita. The lawsuit claims that Fractyl overstated the drug's effectiveness and failed to disclose operational issues in clinical trials, leading to a significant stock price drop after disappointing study results were revealed in January 2026. Investors who bought Fractyl securities between January 2025 and January 2026 are eligible to join the lawsuit, which seeks damages for violations of federal securities laws.
Fractyl Health faces a class action lawsuit over alleged misleading claims about its diabetes and obesity treatment. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 03:02 WIB: out of 128 priced health-sector US stocks, 28 rose and 100 fell. Notable movers include HRTX at USD 0.39 with a 5.32% decline and 61% sell order activity, NUWE at USD 0.64 down 5.27% with 64% buy orders, and TXG at USD 71.71 down 4.63% with 100% buy orders and a typical hold time of 92 days.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Domino's Pizza reported Q3 2026 earnings per share of $4.60, beating analyst expectations of $4.37, while revenue grew modestly by 3.4% to $1.19 billion. Same-store sales growth was minimal at 0.3% in the U.S. and 0.2% internationally, reflecting com...
